Codexis to Participate in the H.C. Wainwright Virtual BioConnect Conference

Rhea-AI Summary

Codexis (Nasdaq:CDXS) announces that President and CEO John Nicols will participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The recorded session will be accessible starting January 11 at 6:00 a.m. ET on the company's investor website, available for 30 days. Codexis specializes in protein engineering, utilizing its CodeEvolver® technology to enhance protein performance for pharmaceuticals, enzymes, and diagnostics, promoting sustainable manufacturing processes.

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that John Nicols, the Company’s President and Chief Executive officer, will participate in a fireside chat presentation at the H.C. Wainwright BioConnect 2021 Conference, being held virtually January 11-14, 2021.

A replay of the pre-recorded fireside chat will be available beginning Monday, January 11, at 6:00 a.m. ET and will be archived on the Investors section of the Company’s website, http://ir.codexis.com/. The recording will be available for a period of 30 days following the event.

About Codexis

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver^® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. More information can be found at www.codexis.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995,. Such forward-looking statements involve substantial risks and uncertainties that could cause Codexis’ future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Codexis undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Codexis’ business in general, please refer to Codexis’ prospectus supplement to be filed with the SEC, including the documents incorporated by reference therein, which include Codexis’ Annual Report on Form 10-K filed with the SEC on February 28, 2020, Codexis’ Quarterly Report on Form 10-Q filed with the SEC on November 6, 2020, and Codexis’ other periodic reports filed with the SEC.

Investor Relations Contact:
Argot Partners
Stephanie Marks/Natallia Clancy
(212)600-1902
Codexis@argotpartners.com

FAQ

When will Codexis' fireside chat at the H.C. Wainwright BioConnect 2021 Conference take place?

The fireside chat will be held virtually from January 11-14, 2021.

How can I access the recorded fireside chat with Codexis' CEO?

The recorded fireside chat will be available starting January 11 at 6:00 a.m. ET on Codexis' investor website.

What technology does Codexis use for protein engineering?

Codexis employs its proprietary CodeEvolver® technology for protein engineering.

What industries does Codexis' technology serve?

Codexis' technology is used in pharmaceuticals, fine chemicals, industrial enzymes, and molecular diagnostics.

For how long will the replay of the Codexis fireside chat be available?

The replay will be available for 30 days following the event.